Message from the Editor-in Chief
暂无分享,去创建一个
1. (29) Sakata Y, Shimokawa H. Epidemiology of heart failure in Asia. Circ J 2013; 77: 2209 – 2217. 2. (28) Swift DL, Lavie CJ, Johannsen NM, Arena R, Earnest CP, O’Keefe JH, et al. Physical activity, cardiorespiratory fitness, and exercise training in primary and secondary coronary prevention. Circ J 2013; 77: 281 – 292. 3. (27) Elrod JW, Molkentin JD. Physiologic functions of cyclophilin D and the mitochondrial permeability transition pore. Circ J 2013; 77: 1111 – 1122. 4. (24) Matsubara J, Sugiyama S, Akiyama E, Iwashita S, Kurokawa H, Ohba K, et al. Dipeptidyl peptidase-4 inhibitor, sitagliptin, improves endothelial dysfunction in association with its anti-inflammatory effects in patients with coronary artery disease and uncontrolled diabetes. Circ J 2013; 77: 1337 – 1344. 5. (21) Sato N, Kajimoto K, Keida T, Mizuno M, Minami Y, Yumino D, et al; on behalf of the ATTEND investigators. Clinical features and outcome in hospitalized heart failure in Japan (from the ATTEND Registry). Circ J 2013; 77: 944 – 951. 6. (20) Inoue H, Okumura K, Atarashi H, Yamashita T, Origasa H, Kumagai N, et al; on behalf of the J-RHYTHM Registry investigators. Target international normalized ratio values for preventing thromboembolic and hemorrhagic events in Japanese patients with non-valvular atrial fibrillation: Results of the J-RHYTHM Registry. Circ J 2013; 77: 2264 – 2270. (20) Murakoshi N, Aonuma K. Epidemiology of arrhythmias and sudden cardiac death in Asia. Circ J 2013; 77: 2419 – 2431. (20) De Paoli F, Staels B, Chinetti-Gbaguidi G. Macrophage phenotypes and their modulation in atherosclerosis. Circ J 2014; 78: 1775 – 1781. 9. (18) Fukumoto Y, Yamada N, Matsubara H, Mizoguchi M, Uchino K, Yao A, et al. Double-blind, placebo-controlled clinical trial with a Rho-kinase inhibitor in pulmonary arterial hypertension: A pilot efficacy trial. Circ J 2013; 77: 2619 – 2625. (18) De Rosa S, Curcio A, Indolfi C. Emerging role of microRNAs in cardiovascular diseases. Circ J 2014; 78: 567 – 575. (18) JCS Joint Working Group. Guidelines for non-pharmacotherapy of cardiac arrhythmias (JCS 2011): Digest version. Circ J 2013; 77: 249 – 274. 12. (17) Annema W, von Eckardstein A. High-density lipoproteins: Multifunctional but vulnerable protections from atherosclerosis. Circ J 2013; 77: 2432 – 2448. (17) Saito S, Isshiki T, Kimura T, Ogawa H, Yokoi H, Nanto S, et al. Efficacy and safety of adjusted-dose prasugrel compared with clopidogrel in Japanese patients with acute coronary syndrome: The PRASFIT-ACS study. Circ J 2014; 78: 1684 – 1692. 14. (16) JCS Joint Working Group. Guidelines for pharmacotherapy of atrial fibrillation (JCS 2013): Digest version. Circ J 2014; 78: 1997 – 2021. (16) Okita K, Kinugawa S, Tsutsui H. Exercise intolerance in chronic heart failure: Skeletal muscle dysfunction and potential therapies. Circ J 2013; 77: 293 – 300. 16. (15) Tsuboi S, Miyauchi K, Kasai T, Ogita M, Dohi T, Miyazaki T, et al. Impact of red blood cell distribution width on long-term mortality in diabetic patients after percutaneous coronary intervention. Circ J 2013; 77: 456 – 461. 17. (14) JCS Joint Working Group. Guidelines for diagnosis and treatment of aortic aneurysm and aortic dissection (JCS 2011): Digest version. Circ J 2013; 77: 789 – 828. Message From the Editor-in-Chief